Please provide your email address to receive an email when new articles are posted on . At 52 weeks, MASH resolution without worsening of fibrosis was reported among 36% on denifanstat vs. 13% on ...
Multicenter Randomized Trial of Adjuvant Fluorouracil and Folinic Acid Compared With Surgery Alone After Resection of Colorectal Liver Metastases: FFCD ACHBTH AURC 9002 Trial From a cohort of 303 ...
NORCROSS, Ga., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (GALT) (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the ...
Researchers have examined cellular crosstalk between the gut and liver during sepsis, helping us better understand sepsis ...
The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their clinical trials. The agency gave a green light to the AI-Based Histologic ...
Nonetheless, the authors concluded, “Liver biopsy is considered the gold standard for diagnosing MASH and MASLD. While ...
Semaglutide significantly improved liver fibrosis and steatohepatitis resolution in MASH patients over 72 weeks compared to placebo. The study involved 800 patients receiving semaglutide and 400 ...
Zdenek Hel, Ph.D., a professor in the UAB Department of Pathology’s Division of Molecular and Cellular Pathology, received a five-year, $3.6 million R01 to support his project, “Dysregulated ...
ACC, Acetyl-CoA Carboxylase; PPAR, peroxisome proliferator–activated receptor; MPC, mitochondrial pyruvate carrier; THR, thyroid hormone receptor; ASK-1, apoptosis signaling kinase-1; GLP-1R, glucagon ...
Non-alcoholic fatty liver disease (NAFLD) and the more-recently coined term metabolic dysfunction-associated fatty liver disease (MAFLD) are used interchangeably. 1 The investigators of a newly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback